Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer 4Q Revenues Down 41% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Pfizer 4Q Revenues Down 41%

Decline in Comirnaty and Paxlovid revenues drove 42% operational decrease in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
4Q Revenues: $14.2 billion (-41%)
4Q Loss: $3.4 billion (earnings were $5.0 billion 4Q22)
FY Revenues: $58.5 billion (-42%)
FY Earnings: $2.1 billion (-93%)
Comments: Decline in Comirnaty and Paxlovid revenues drove 42% operational decrease in the quarter. Biopharmaceuticals business sales were down 42% in the quarter to $13.9 billion.
Primary Care sales were down 60% to $7.0 billion. Specialty care sales were up 11% to $3.9 billion. Oncology sales were down 3% to $2.9 billion in the quarter.
 
Abrysvo contributed $515 million in global revenues in the quarter, driven primarily by launch of the older adult indication in the U.S. in July 2023. Vyndaqel family sales were up 39% operationally, driven largely by continued uptake of the transthyretin amyloid cardiomyopathy (ATTR-CM) indication. Global Eliquis sales were up 9% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication, partially offset by declines due to loss of exclusivity and generic competition in certain international markets.
 
Global Ibrance sales were down 13% operationally, driven primarily by lower demand globally due to competition and lower clinical trial purchases in certain international markets.
Global Prevnar family sales were down 7% operationally, driven primarily by the pediatric indication in emerging markets due to lower demand and unfavorable timing of customer orders.
 
R&D expenses were $2.8 billion in the quarter, down 22%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters